{"id":2674,"date":"2018-11-05T14:19:07","date_gmt":"2018-11-05T13:19:07","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=2674"},"modified":"2020-09-28T15:20:40","modified_gmt":"2020-09-28T13:20:40","slug":"genkyotex-biodiscovery-3-atteint-les-criteres-intermediaires-defficacite-principal-et-secondaires-dans-son-etude-de-phase-2-avec-le-gkt831-dans-la-cholangite-biliaire-primitive","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/genkyotex-biodiscovery-3-atteint-les-criteres-intermediaires-defficacite-principal-et-secondaires-dans-son-etude-de-phase-2-avec-le-gkt831-dans-la-cholangite-biliaire-primitive\/","title":{"rendered":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-2675\" src=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\" alt=\"\" width=\"404\" height=\"223\" srcset=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png 404w, https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex-285x157.png 285w, https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex-385x213.png 385w\" sizes=\"auto, (max-width: 404px) 100vw, 404px\" \/><\/p>\n<p>Apr\u00e8s seulement 6 semaines de traitement, les taux de gamma glutamyl\u00a0transpeptidase (GGT) ont diminu\u00e9 de 23% dans le groupe de patients prenant\u00a0400 mg de GKT831 deux fois par jour\u00a0 (p&lt;0.01)<\/p>\n<p>Chez les patients avec des taux initiaux de GGT plus \u00e9lev\u00e9s, la r\u00e9duction de GGT est encore plus importante \u00e0 29% (p&lt;0.01)<\/p>\n<p>Les taux de phosphatase alcaline (PAL) sont r\u00e9duits de 17% dans le groupe de\u00a0patients prenant 400 mg de GKT831 deux fois par jour (p&lt;0.001)<\/p>\n<p>Pour le lire le communiqu\u00e9 de presse dans son int\u00e9gralit\u00e9, <a href=\"https:\/\/www.newcontact.eu\/secure\/media\/com_newcap\/files\/files\/2018.11.05%20Genkyotex%20CP%20interim%20efficacy%20results%20FINAL_FR.pdf\">cliquez ici<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apr\u00e8s seulement 6 semaines de traitement, les taux de gamma glutamyl\u00a0transpeptidase (GGT) ont diminu\u00e9 de 23% dans le groupe de patients prenant\u00a0400 mg de GKT831 deux fois par jour\u00a0 (p&lt;0.01) Chez les patients avec des taux initiaux de GGT plus \u00e9lev\u00e9s, la r\u00e9duction de GGT est encore plus importante \u00e0 29% (p&lt;0.01) Les taux de&#8230;<\/p>\n","protected":false},"author":2,"featured_media":2675,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-2674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Apr\u00e8s seulement 6 semaines de traitement, les taux de gamma glutamyl\u00a0transpeptidase (GGT) ont diminu\u00e9 de 23% dans le groupe de patients prenant\u00a0400 mg de GKT831 deux fois par jour\u00a0 (p&lt;0.01) Chez les patients avec des taux initiaux de GGT plus \u00e9lev\u00e9s, la r\u00e9duction de GGT est encore plus importante \u00e0 29% (p&lt;0.01) Les taux de...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-05T13:19:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-28T13:20:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\" \/>\n\t<meta property=\"og:image:width\" content=\"404\" \/>\n\t<meta property=\"og:image:height\" content=\"223\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline\",\"datePublished\":\"2018-11-05T13:19:07+00:00\",\"dateModified\":\"2020-09-28T13:20:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"},\"wordCount\":108,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\",\"name\":\"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"datePublished\":\"2018-11-05T13:19:07+00:00\",\"dateModified\":\"2020-09-28T13:20:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png\",\"width\":404,\"height\":223},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","og_locale":"fr_FR","og_type":"article","og_title":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS","og_description":"Apr\u00e8s seulement 6 semaines de traitement, les taux de gamma glutamyl\u00a0transpeptidase (GGT) ont diminu\u00e9 de 23% dans le groupe de patients prenant\u00a0400 mg de GKT831 deux fois par jour\u00a0 (p&lt;0.01) Chez les patients avec des taux initiaux de GGT plus \u00e9lev\u00e9s, la r\u00e9duction de GGT est encore plus importante \u00e0 29% (p&lt;0.01) Les taux de...","og_url":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2018-11-05T13:19:07+00:00","article_modified_time":"2020-09-28T13:20:40+00:00","og_image":[{"width":404,"height":223,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","type":"image\/png"}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline","datePublished":"2018-11-05T13:19:07+00:00","dateModified":"2020-09-28T13:20:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"},"wordCount":108,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","url":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/","name":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","datePublished":"2018-11-05T13:19:07+00:00","dateModified":"2020-09-28T13:20:40+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/11\/genkyotex.png","width":404,"height":223},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/genkyotex-meets-both-primary-and-secondary-interim-efficacy-endpoints-in-phase-2-trial-of-gkt831-in-primary-biliary-cholangitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"R\u00e9sultats prometteurs pour le candidat-m\u00e9dicament principal de Genkyotex (BioDiscovery 3) dans une maladie fibrotique orpheline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/2674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=2674"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/2674\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media\/2675"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=2674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=2674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}